Skip to main content

Table 2 Summary of MOS-HIV physical and mental health summary scores in NNRTI clinical trials

From: Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies

Citation Treatment/dosing regimen Follow-up period Physical health summary scores Mental health summary scores
Baseline Follow-up Significance Baseline Follow-up Significance
Mean (SD) Mean Over time Between groups Mean (SD) Mean Over time Between groups
Randomized controlled trials
Chang et al. (2007) Intervention: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to tapes with instructions to elicit the relaxation response via earphones, followed by soft music played in the clinic 4 weeks 57.5 (21.1) 61.3 N N 57.5 (17.0) 62.9 Y N
8 weeks 62.7 N N 62.8 N N
12 weeks 65.6 Y N 68.1 Y N
Control: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to soft music played in the clinic 4 weeks 62.0 (21.4) 66.7 N N 64.1 (17.9) 71.0 Y N
8 weeks 66.4 N N 69.5 N N
12 weeks 65.7 N N 70.7 N N
Bucciardini et al. (2007) Didanosine + stavudine + efavirenz 1 year 50 (11) 54.7 N N 49 (10) 53.0 N N
2 years   54.9 N N   50.4 N N
3 years   54.9 N N   49.5 N N
Didanosine + stavudine + nelfinavir 1 year 46 (13) 46.7 N N 48 (10) 50.8 N N
2 years   49.2 N N   51.5 N N
3 years   50.9 N N   53.5 N N
Didanosine + stavudine + efavirenz + nelfinavir 1 year 48 (12) 50.0 N N 50 (9) 50.0 N N
2 years 48.1 N N 49.5 N N
3 years 50.0 N N 53.4 N N
Huang et al. (2008) Tipranavir + ritanovir 48 weeks 48.0 (11.3) 48.2 NM N 47.8 (10.5) 49.2 NM N
Boosted comparitor protease inhibitor 48 weeks 47.1 (10.9) 46.8 NM N 46.9 (10.3) 48.6 NM N
Lafaurie et al. (2008) Maintenance of a stable protease inhibitor-containing regimen 48 weeks NR −1.04 NM N NR 0.00 NM N
Switch to efavirenz + didanosine + emtricitabine once-daily 48 weeks NR −1.76 NM N NR 1.01 NM N
Sprinz et al. (2006) Immediate substitution with lopinavir/ritonavir 400/200 mg twice daily 4 weeks 49.44 52.06 Y Y 46.7 50.79 Y Y
8 weeks   52.38 Y Y   51.34 Y Y
Deferred (week 4) substitution with lopinavir/ritonavir 400/100 mg twice daily 4 weeks 50.32 49.71 N Y 48.25 48.03 N Y
8 weeks 51.12 N Y 50.02 Y Y
Nuesch et al. (2009) Continuous treatment 24 weeks 53.8 (6.6) 52.7 N N 51.7 (7.6) 52.7 Y Y
48 weeks 52.5 N N 52.5 Y Y
CD4-guided scheduled treatment interruption (CD4 threshold of 350 cells/μL for interruption/re-initiation of ARV therapy) 24 weeks 54.4 (6.3) 53.2 N N 49.1 (8.3) 48.1 Y Y
48 weeks 53.2 N N 49.5 Y Y
Powers et al. (2006) Intermittent treatment (7 cycles of 4 weeks off/8 weeks on HAART) 4 weeks 54.2 (8.3) 54.2 N Y 54.0 (8.8) 53.56 N Y
12 weeks   55.55 N Y   57.45 Y Y
40 weeks   54.76 N Y   57.22 Y Y
Continuous treatment (continue regimen for 22 weeks) 4 weeks 53.0 (11.5) 53.27 N Y 53.8 (15.7) 53.36 N Y
12 weeks   52.97 N Y   57.25 N Y
40 weeks   54.00 N Y   57.02 N Y
Wu et al. (2006) Disease Management Assistance System + education 6 months 45.7 (11.0) 44.2 NR Y 49.2 (10.3)* 49.5 NR N
Education only 6 months 41.2 (12.7) 47.0 NR Y 40.7 (12.4)* 44.9 NR N
Non-randomized controlled trials
Shalit et al. (2007) Enfuvirtide + ARTs 12 weeks NR 2.21 Y N/A NR 2.91 Y N/A
Levine et al. (2008) Epoetin alfa + iron supplementation (in addition to current ART regimen) MPD1 38.5 (12.0) 43.0 N N/A 42.4 (11.2) 47.8 N N/A
24 weeks 43.5 Y N/A 47.5 Y N/A
Stangl et al. (2007) HAART and weekly home visits by study staff that re-supplied HAART and other drugs, conducted a pill count, and assessed participants’ health 3 months 39.2 (9.8) 50.6 Y N/A 40.0 (11.2) 50.2 Y N/A
6 months 53.0 Y N/A 53.0 Y N/A
9 months 53.6 Y N/A 54.2 Y N/A
12 months 54.2 Y N/A 54.2 Y N/A
  1. *significant difference in baseline scores (P=0.01).